M
Malcolm J. Moore
Researcher at Princess Margaret Cancer Centre
Publications - 238
Citations - 45832
Malcolm J. Moore is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Gemcitabine & Cancer. The author has an hindex of 64, co-authored 231 publications receiving 42222 citations. Previous affiliations of Malcolm J. Moore include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: Gemcitabine with or without chemoradiotherapy and with or without erlotinib—LAP 07 study.
Pascal Hammel,Florence Huguet,J.-L. Van Laethem,David Goldstein,Bengt Glimelius,Malcolm J. Moore,Benoist Chibaudel,F. Bonnetain,C. Louvet,glimelius +9 more
TL;DR: The role of CRT with quality control in patients whose tumor has been firstly controlled by CT, and the role of erlotinib in this disease are addressed.
Journal ArticleDOI
Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia
Eric Winquist,Jim A. Julian,Malcolm J. Moore,Abdenour Nabid,Jinka Sathya,Lori Wood,Peter Venner,Mark Levine +7 more
Journal Article
Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity
TL;DR: The data support the use of 9-AC by infusion for 24 h or longer in clinical studies providing target plasma concentrations can be achieved and cytotoxicity was limited and less than 1 log of cell killing occurred, even with very high drug concentrations.
Journal ArticleDOI
Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.
Lillian L. Siu,Jeremy Shapiro,Derek J. Jonker,Christos S. Karapetis,John Zalcberg,John Simes,Félix Couture,Malcolm J. Moore,Timothy J. Price,Jehan Siddiqui,Louise M. Nott,Danielle Charpentier,Winston Liauw,Michael B. Sawyer,Michael Jefford,Nadine M Magoski,Andrew Haydon,Ian Walters,Dongsheng Tu,Christopher J. O'Callaghan +19 more
TL;DR: The anti-EGFR monoclonal antibody CET has improved survival in pts with chemotherapy refractory, K-RAS WT mCRC and demonstrated encouraging activity in an early phase clinical trial.
Journal ArticleDOI
A phase I study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in combination with gemcitabine (GEM) in patients (pts) with advanced pancreatic cancer
Jean-Philippe Spano,Malcolm J. Moore,Sinil Kim,K. F. Liau,B. Hee,Paul Bycott,P. Boissaye,S. Francis,D. Peters,Olivier Rixe +9 more
TL;DR: This combination is safe and appears to be an effective treatment for advanced pancreatic cancer with significant tumor regression observed in 2 pts and Radiological assessment suggests 2 pts with partial response and 4 pts with stable disease: response assessments are ongoing.